Immune checkpoint-inhibitors and chemoradiation in stage III unresectable non-small cell lung cancer.
Explore this paper's citation graph
Summary
Stage III data from the PACIFIC trial show significantly improved progression-free survival for the checkpoint-inhibitor durvalumab given as consolidation following definitive chemoradiotherapy (cCRT), now representing a new standard of care.
- Type
- review
- Published
- 2019-08-01
- Cited by
- 31
- References
- 69
- OpenAlex
- https://openalex.org/W2946988148
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:190864443
Keywords
Durvalumab, Medicine, Oncology, Lung cancer, Pneumonitis
References
- Adjuvant radiation therapy in locally advanced non-small cell lung cancer: Executive summary of an American Society for Radiation Oncology (ASTRO) evidence-based clinical practice guideline.
- Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer.
- Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study
- Immunologic and Clinical Effects of Targeting PD-1 in Lung Cancer
- Pembrolizumab for the treatment of non-small-cell lung cancer.
- Hyperfractionated or accelerated radiotherapy in lung cancer: an individual patient data meta-analysis.
- The abscopal effect of local radiotherapy: using immunotherapy to make a rare event clinically relevant
- A Phase III randomized study of interleukin‐2 lymphokine‐activated killer cell immunotherapy combined with chemotherapy or radiotherapy after curative or noncurative resection of primary lung carcinoma
- Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice.
- The blockade of immune checkpoints in cancer immunotherapy
- Immune Checkpoint Blockade in Cancer Therapy.
- Definitive and Adjuvant Radiotherapy in Locally Advanced Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Endorsement of the American Society for Radiation Oncology Evidence-Based Clinical Practice Guideline.
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
- Nivolumab versus Docetaxel in Advanced Non-squamous Non-small Cell Lung Cancer
- Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer.
- Induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for regionally advanced unresectable stage III Non-small-cell lung cancer: Cancer and Leukemia Group B.
- Molecular Pathways: Next-Generation Immunotherapy—Inhibiting Programmed Death-Ligand 1 and Programmed Death-1
- PD-1 Restrains Radiotherapy-Induced Abscopal Effect
- Telomerase Peptide Vaccination in NSCLC: A Phase II Trial in Stage III Patients Vaccinated after Chemoradiotherapy and an 8-Year Update on a Phase I/II Trial
- Phase III study of cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel in patients with inoperable stage III non-small-cell lung cancer: the Hoosier Oncology Group and U.S. Oncology.
Cited by
- Compound Kushen Injection as an Adjunctive Therapy for the Treatment of Non-Small-Cell Lung Cancer: A Meta-Analysis of Randomized Controlled Trials
- Circular RNA circFGFR1 promotes progression and anti-PD-1 resistance by sponging miR-381-3p in non-small cell lung cancer cells
- Immune Checkpoint Inhibitors for the Treatment of Unresectable Stage III Non–Small Cell Lung Cancer: Emerging Mechanisms and Perspectives
- Circular RNA SMARCA5 may serve as a tumor suppressor in non‐small cell lung cancer
- Radiation dose escalation with modified fractionation schedules for locally advanced NSCLC: A systematic review
- Epidemiology of stage III lung cancer: frequency, diagnostic characteristics, and survival
- Surgery after neoadjuvant immunotherapy in patients with resectable non-small cell lung cancer
- Intracranial radiotherapy with or without immune checkpoint inhibition for brain metastases: a systematic review and meta-analysis
- Anti-PD-L1 DNA aptamer antagonizes the interaction of PD-1/PD-L1 with antitumor effect.
- Insights Into circRNAs: Functional Roles in Lung Cancer Management and the Potential Mechanisms
- Unravelling the Role of LncRNA WT1-AS/miR-206/NAMPT Axis as Prognostic Biomarkers in Lung Adenocarcinoma
- Exploration of Tumor Mutation Burden Combined with Immune Infiltrates in the Prognosis of Lung Adenocarcinoma
- Molecular and Clinical Premises for the Combination Therapy Consisting of Radiochemotherapy and Immunotherapy in Non-Small Cell Lung Cancer Patients
- Canakinumab with and without pembrolizumab in patients with resectable non-small-cell lung cancer: CANOPY-N study design.
- Genotoxic Treatment Enhances Immune Response in a Genetic Model of Lung Cancer
- CheckMate 73L: A Phase 3 Study Comparing Nivolumab Plus Concurrent Chemoradiotherapy Followed by Nivolumab With or Without Ipilimumab Versus Concurrent Chemoradiotherapy Followed by Durvalumab for Previously Untreated, Locally Advanced Stage III Non-Small-Cell Lung Cancer.
- Real-World Incidence of Pneumonitis in Patients Receiving Durvalumab.
- Prospective trial of immuno(chemo)therapy before resection, definitive chemoradiotherapy or palliative therapy in patients with locally advanced or oligometastatic non-small cell lung cancer without a primary curative option.
- Smoking status combined with tumor mutational burden as a prognosis predictor for combination immune checkpoint inhibitor therapy in non‐small cell lung cancer
- Clinical Management and Outcome of Grade III Pneumonitis after Chemoradioimmunotherapy for Inoperable Stage III Non-Small Cell Lung Cancer—A Prospective Longitudinal Assessment
Related papers
- Implications of pneumonitis after chemoradiation and durvalumab for locally advanced non-small cell lung cancer
- Clinical outcome of early development of pneumonitis in non-small cell lung cancer patients treated with durvalumab
- Pneumonitis after chemoradiation and adjuvant durvalumab in stage III non-small-cell lung cancer.
- Predictors of Pneumonitis in Patients With Locally Advanced Non-Small Cell Lung Cancer Treated With Definitive Chemoradiation Followed by Consolidative Durvalumab
- Durvalumab After Sequential Chemoradiotherapy Is Safe for Stage III, Unresectable NSCLC: Results From Phase 2 PACIFIC-6 Trial.
- Immune‐mediated thrombocytopenia induced with durvalumab after chemoradiotherapy in a non‐small cell lung cancer patient: A case report
- A comparison of standard chemoradiotherapy treatment to standard chemoradiotherapy treatment given in combination with durvalumab to see if the addition of durvalumab leads to improved survival
- Acute-Onset Pneumonitis while Administering the First Dose of Durvalumab
- Impact of TMB/PD-L1 expression and pneumonitis on chemoradiation and durvalumab response in stage III NSCLC
- P09.54 Pneumonitis Following Durvalumab: A Real-World Analysis in Patients with Lung Cancer and Other Tumor Types